



RESEARCH ARTICLE

REVISED Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire based hypothetical study [version 2; peer review: 2 approved]

FARAZ MOHAMMED ¹, ARISHIYA THAPASUM FAIROZEKHAN¹, SHAMAZ MOHAMED², SAUD ABDULLAH ALMOUMEN^{3,4}, AMR S. BUGSHAN ¹, ZAINAB I. ALMOMEN⁵, AMINAH MOHAMMAD ALMOMEN⁶, SHASHI KIRAN M⁷, KHALID S. ALMULHIM ⁸

¹Department of Biomedical Dental Sciences, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, P.O. Box 1982, Saudi Arabia

²Senior Manager, BioQuest Solutions Pvt Ltd, Bangalore, Karnataka, India

³Oral & Maxillofacial Surgery - Dental Division, Ministry of Health, Dammam, Eastern Province, Saudi Arabia

⁴Postgraduate Scholar, Oral & Maxillofacial Surgery, Riyadh Elm University, Riyadh, Saudi Arabia

⁵Medical Intern, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, P.O. Box 1982, Saudi Arabia

⁶Medical graduate, Private Practice, Dammam, Eastern Province, Saudi Arabia

⁷Manager, BioQuest Solutions Pvt Ltd, Bangalore, Karnataka, India

⁸Department of Restorative Dental Sciences, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Saudi Arabia

V2 First published: 06 Dec 2022, 11:1443
<https://doi.org/10.12688/f1000research.128125.1>

Latest published: 23 May 2023, 11:1443
<https://doi.org/10.12688/f1000research.128125.2>

Abstract

Background: Since the Coronavirus disease 2019 (COVID-19) outbreak in 2019, the virus has evolved drastically, presenting with sets of mutations that influence its properties, including transmissibility and antigenicity. The oral mucosa is postulated as probable portal entry and several oral manifestations have been identified, which places dental professionals in a position to recognize probable COVID-19 patients depending on oral signs and symptoms in the initial phases of the disease itself. As co-existing with COVID-19 seems to be a new reality, greater understanding is required regarding early oral signs and symptoms which can be predictors for timely intervention and prevention of complications in COVID-19 patients. The objective of the study is to identify the distinguishing oral signs and symptoms among COVID-19 patients and to establish possible correlation between severity of COVID-19 infection and oral symptoms.

Methods: This study recruited 179 ambulatory, non-hospitalized COVID-19 patients from the Kingdom of Saudi Arabia's Eastern Province's designated hotels for COVID-19 and home isolated patients from the same region using a convenience sample method. Data was collected by qualified and experienced investigators, including two

Open Peer Review

Approval Status

	1	2
version 2 (revision) 23 May 2023	 view	 view
version 1 06 Dec 2022	 view	 view

1. **Muhammad Amber Fareed** , Gulf Medical University, Ajman, United Arab Emirates

2. **Shruthi Acharya** , Manipal Academy of Higher Education, Manipal, India

Any reports and responses or comments on the article can be found at the end of the article.

physicians and three dentists, using a validated comprehensive questionnaire through telephonic interviews with the participants. The χ^2 was used to assess the categorical variables, and odd's ratio was calculated to determine the strength of the association between general symptoms and oral manifestations.

Results: Oral and nasopharyngeal lesions or conditions like loss of smell and taste, xerostomia, sore throat, and burning sensation were predictors of COVID-19-related systemic symptoms such as cough, fatigue, fever, and nasal congestion were identified to be statistically significant ($p < 0.05$).


Conclusions: The study reveals the occurrence of olfactory or taste dysfunction, dry mouth, sore throat, and burning sensation along with COVID-19 generic symptoms, should be considered as suggestive yet not conclusive indicators of COVID-19.

Keywords

COVID-19, oral symptoms, prevalence, anosmia, ageusia, xerostomia.



This article is included in the **Emerging Diseases and Outbreaks** gateway.



This article is included in the **Coronavirus** collection.

Corresponding author: ARISHIYA THAPASUM FAIROZEKHAH (afairozekhan@iau.edu.sa)

Author roles: **MOHAMMED F:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **FAIROZEKHAH AT:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **MOHAMED S:** Conceptualization, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **ALMOUMEN SA:** Data Curation, Investigation, Resources, Visualization, Writing – Review & Editing; **BUGSHAN AS:** Conceptualization, Data Curation, Methodology, Project Administration, Supervision; **ALMOMEN ZI:** Data Curation, Investigation, Resources, Writing – Review & Editing; **ALMOMEN AM:** Data Curation, Investigation, Resources, Writing – Review & Editing; **M SK:** Conceptualization, Formal Analysis, Methodology, Software, Validation, Visualization; **ALMULHIM KS:** Conceptualization, Investigation, Supervision, Visualization

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2023 MOHAMMED F *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: MOHAMMED F, FAIROZEKHAH AT, MOHAMED S *et al.* **Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire based hypothetical study [version 2; peer review: 2 approved]** F1000Research 2023, 11:1443 <https://doi.org/10.12688/f1000research.128125.2>

First published: 06 Dec 2022, 11:1443 <https://doi.org/10.12688/f1000research.128125.1>

REVISED Amendments from Version 1

According to the comments from the reviewers, we have updated Figure 3. Prevalence of oral lesions and conditions based on location and also updated Table 4. Odds' ratios showing 95% confidence interval and strength of association between Oral/ Nasopharyngeal lesions or conditions and Covid-19 related systemic symptoms.

Any further responses from the reviewers can be found at the end of the article

Introduction

The outbreak of COVID-19 was followed by a span of evolutionary dormancy. The hallmark of this disease is that it goes undetected for particular period of time, either because it lies dormant or because it is present in just trace amounts. COVID-19 was not detected in nasopharyngeal/sputum samples in many of the instances examined.¹ Ever since, COVID-19 has evolved drastically presenting with sets of mutations that influence viral properties, including transmissibility and antigenicity.² The COVID-19 pandemic has spawned a state of stasis across the world for almost two years. The World Health Organization (WHO), reported 229,373,963 diagnosed cases of COVID-19 with 4,705,111 deaths on September 22, 2021.³

Ample clinical and epidemiological evidence suggests that the COVID-19 virus is extraordinarily virulent, contagious and extensively transmissible among populations by respiratory secretions and via contact and fomites.⁴ The oral mucosa is thought to be a probable portal of entry for the COVID-19 virus as its cellular entry receptor ACE2 is present in different tissues of oral mucosa, notably in tongue and floor of the mouth.⁵ With the likelihood of deleterious mutations of COVID-19 virus amidst the new confirmation of effective destruction of some SARS-CoV-2 variants by the newly developed immunizers; it is crucial to have greater understanding of the oral link so that dental professionals can identify potential COVID patients or carriers and provide timely interventions to prevent transmission.

Clinical records have proven that self-reported ageusia and anosmia are strong pointers for the detection of COVID-19 even at a preliminary stage of the disease.⁶ Various COVID-19-related oral symptoms include xerostomia, mucosal ulcerations, sialadenitis, and periodontal disease apart from gustatory dysfunction.⁷ The initial COVID-19 symptom of loss of taste, that often precedes fever and or other symptoms, corroborates the hypothesis that perhaps oral cavity, in particularly mucosal membrane of tongue, might be an early niche of viral infection.⁵

Several underlying mechanisms have been proposed for COVID-19-related oral manifestations. It is possible that dysregulation of the immune system releases inflammatory cytokines that trigger the onset of oral mucosal ulcers.⁷ Several studies have mentioned different strategies by which SARS-CoV-2 may induce dysgeusia in COVID-19 patients.⁸ The proposed mechanisms include neural invasion of the virus into gustatory nerves, direct damage of the taste buds by the virus, angiotensin II hormone imbalance, improper sialic acid function, hyposalivation and hypozincemia.⁸⁻¹³ Direct damage of the salivary glands by the virus, zinc deficiency and inflammatory damage of the glands may cause dry mouth in COVID-19 patients.^{8,13} SARS-CoV-2 is evident in saliva of patients with COVID-19 and proven to be detected by salivary reverse transcriptase-polymerase chain reaction (RT-PCR) as it is a more sensitive and reliable testing tool than nasopharyngeal swab test.¹⁴

Dental professionals by virtue of the nature of dental practice procedures are at an increased risk of being exposed to body fluids. Close positioning of dental staff to the patients implies that COVID-19 patients or asymptomatic carriers could easily disseminate the disease to dental professionals, and vice versa if appropriate and adequate protective measures are not taken.¹⁵

Thus, there are several studies which considered oral transmission to be one of the main routes of COVID-19 infection, but there is still a gap of knowledge regarding the oral manifestations related to COVID-19 and its impact on the oral cavity.¹⁶ This gap could be due to the lower sample size studied. Therefore, this study was designed to identify the distinguishing oral signs and symptoms in COVID-19 patients and to establish a possible correlation between oral symptoms and gravity of COVID-19 infection by overcoming the previous research gaps.

Methods

A survey was carried out to determine the prevalence of oral diagnostic features among patients who were diagnosed with COVID-19. The Institutional Review Board of Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia approved the study (IRB# 2020-02-220).

Inclusion criteria were based on the diagnostic recommendations for new coronavirus pneumonia (NCIP) of the seventh edition to make sure that the patients included in the research, had positively tested for COVID-19 nucleic acid through the use of RT-PCR or/and next-generation sequencing (NGS) methods before collection of data.¹⁶ The study population consisted of ambulatory, non-hospitalized patients who were quarantined in the Kingdom of Saudi Arabia's Eastern Province's designated hotels for COVID-19 and those who were home quarantined in the same region. The contact details of the patients were ethically obtained in an anonymous format, without violating the personal privacy of the patients from the authorized COVID-19 testing laboratories' s Health Electronic Surveillance Network (HESN) database located in the Eastern Province.

A convenience sampling method was adopted for recruiting participants in this study. As it was considerably difficult to get study participants because of the infectious nature of the disease and the social stigma associated with strict COVID-19 protocols, all participants who fulfilled the inclusion requirements and consented were recruited in the study; hence sample size was not taken into consideration. For obtaining consent for participation in the study, a Short Message Service text message (SMS) was sent to all those targeted patients asking them to reply to the same SMS if they were agreeing to involve themselves in the study. Those patients who responded with SMS consent were recruited in the study. Later, one-to-one telephonic interviews were conducted with the respective patients, based on the survey questionnaire, by qualified and experienced investigators including two physicians and three dentists. The study conducted from 21/08/2020 to 07/12/2020.

Data collection was done by means of a comprehensive survey questionnaire which was converted into an online format by using the **QuestionPro**[®] software, to enquire about the systemic and oral manifestation related symptoms of COVID-19 patients. The questionnaire was in accordance with the current literature available about the novel SARS-CoV-2 and COVID-19, including its unique properties, signs and symptoms, recovery after infection, and methods of prevention. The initial component of the survey form included basic demographic details of the participating patients such as age group, gender and type of profession. The latter part of the questionnaire evaluated the COVID-19-related oral and general signs and symptoms. Patients were also asked to report any history of underlying comorbid conditions like diabetes mellitus, hypertension etc. and psychosocial habits including tobacco and substance abuse. The last part of the questionnaire included the questions related to recovery from COVID-19 infection.

The questionnaire was checked for face validity by two independent reviewers. Further, to guarantee the clarity and validity of the questions, the survey form was pilot tested on 15 patients. Based on the responses obtained from the pilot study, certain modifications were made; for the same reason these results were eliminated from the final data which was considered for final analysis. Data collection was based only on telephonic interviews and no clinical examination was performed on any of the study subjects.

Statistical analysis

The Statistical Package for Social Sciences Software (SPSS V-22, Armonk, NY: IBM Corp) was used to analyse the data. Results were summarised and displayed as frequency distribution tables. The X^2 was used to assess the categorical variables, and odd's ratio was calculated to determine the strength of the association between general symptoms and oral manifestations. Statistical significance was inferred when the p value was ≤ 0.05 .

Results

The current study was designed to obtain insights about the various oral and nasopharyngeal lesions or conditions among patients with history of COVID-19. Participation in this research study was agreed by 230 patients by SMS. Only 179 COVID-19 patients were included for the analysis as few of them did not respond to most questions telephonically. Data analysis was done based on responses obtained from these 179 COVID-19 patients. According to sociodemographic data (**Figure 1**), the study population comprised of female patients (57.0%) and male patients (43.0%). The subjects were divided into six age groups, with the largest proportion (29%) belonging to those aged between 21 and 30 years, and the smallest proportion (5.0%) to those aged under 10 years. The vast majority of subjects (82.7%) were not health professionals, with only a handful (17.3%) working in hospitals as COVID-19 warriors.

Considering COVID-19 related symptoms (**Table 1**), the order of prevalence in decreasing order were fatigue (75.0%), body pain (74.1%), headache (64.1%), cough (58.7%), fever (55.2%), dizziness (51.5%), subjective fever (48.77%), diarrhea (42.9%), runny nose (37.3%), nasal congestion (32.3%) and shortness of breath (26.1%). Most of the subjects reported that these symptoms had begun before initiation of COVID-19 related treatment. Fever without chills (61.1%) and dry cough (63%) were relatively more common among the study subjects than fever with chills or productive cough.




Figure 1. Demographic details of study population.

Table 1. Prevalence of COVID-19 related symptoms of the study population.

Cough (179)	Yes-105(58.7%)	No-74(41.3%)	
Type of cough (100)	Dry cough-63(63%)	Cough with phlegm-37 (37%)	
Cough had started (98)	Before the treatment	During the treatment	After the treatment
	84(85.7%)	12(12.2%)	2(2.1%)
Headache (170)	Yes -109(64.1%)	No- 61(35.9%)	
Headache had started (109)	Before the treatment	During the treatment	After the treatment
	97(89%)	11(10.1%)	1(0.9%)
Body pain (170)	Yes-126(74.1%)	No-44(25.9%)	
Body pain had started (125)	Before the treatment	During the treatment	
	104(83.2%)	21(16.8%)	
Fatigue (168)	Yes-126(75.0%)	No-42(25.0%)	
Fatigue Started (123)	Before the treatment	During the treatment	After the treatment
	100(81.3%)	22(17.9%)	1(0.8%)
Dizziness (163)	Yes -84(51.5%)	No-79(48.5%)	
Dizziness started (84)	Before the treatment	During the treatment	After the treatment
	68(81.0%)	14(16.7%)	2(2.3%)
Fever (163)	Yes-90(55.2%)	No-73(44.8%)	
Type of Fever (90)	With chills-35(38.9%)	Without chills-55(61.1%)	
Fever had started (90)	Before the treatment	During the treatment	
	83(92.2%)	7(7.8%)	
Subjective fever (162)	Yes-79(48.77%)	No-83(51.23%)	
Subjective fever started (79)	Before the treatment	During the treatment	After the treatment
	54(68.35%)	24(30.38%)	1(1.27%)
Shortness of breath (161)	Yes- 42(26.1%)	No-119(73.9%)	
Shortness of breath started (42)	Before the treatment	During the treatment	After the treatment
	33(78.6%)	7(16.7%)	2(4.7%)
Runny Nose (161)	Yes- 60(37.3%)	No-101(62.7%)	

Table 1. Continued

Runny Nose started (60)	Before the treatment-49 (81.7%)	During the treatment-11(18.3%)	
Nasal congestion (161)	Yes-52(32.3%)	No-109(67.7%)	
Nasal congestion started (52)	Before the treatment	During the treatment	
	34(65.4%)	18(34.6%)	
Diarrhea (161)	Yes-69(42.9%)	No-92(57.1%)	
Diarrhea started (69)	Before the treatment	During the treatment	After the treatment
	48(69.6%)	18(26.1%)	3(4.3%)




Figure 2. Oral and Nasopharyngeal lesions and conditions among study subjects.

According to frequency distribution of Oral and Nasopharyngeal lesions or conditions (Figure 2), Loss of smell (61.9%), Loss of taste (51.9%), Xerostomia (22.1%), Sore throat (19.2%), Burning sensation (11.3%), Xerostomia with Burning sensation (8.9%), Ulcers (8.2%), Vesicles (7.0%), Altered taste (5.0%), Tingling sensation (3.8%) and Papules (3.2%) were reported in decreasing order of frequency by study subjects when they were down with COVID-19.

Regarding the prevalence of oral lesions and conditions based on location (Figure 3), Gingiva was found to be the most common site for the occurrence of Burning sensation (5.0%) and ulcers (4.4%). The tingling sensation was most frequently felt on posterior tongue, lips, and floor of the mouth (1.3%). The lips were the most common location for vesicles (2.5%) while the most frequent sites for occurrence of papules were uvula and tonsils (1.9%).

The frequency distribution of oral and nasopharyngeal lesions and conditions associated with COVID-19 in different age groups (Table 2) revealed statistically significant differences (p<0.05) with regard to sore throat, loss of taste and smell. The '21 to 30' and '31 to 40' age groups reported the greatest frequency of loss of taste and smell, followed by the '41 to 50' age group. Loss of smell was least common among children below 10 years of age and none of these children experienced loss of taste. The incidence of sore throat was highest among 41 to 50 years old and lowest among those aged 10 to 20 years age groups.

Gender based comparison for occurrence of Oral and Nasopharyngeal lesions or conditions (Table 3) showed that Anosmia, Ageusia, Xerostomia, Sore throat, Burning sensation and Vesicles were more commonly reported by females while males had a higher prevalence of ulcers; however these differences were statistically insignificant (p>0.05).

Odds' ratios showing strength of association (Table 4) showed that Oral/Nasopharyngeal lesions or conditions like Anosmia, Ageusia, Xerostomia, Sore throat and Burning Sensation can be predictors of COVID-19 related systemic symptoms like cough, fatigue, subjective fever and nasal congestion were found to be statistically significant (p<=0.05).




Figure 3. Prevalence of oral lesions and conditions based on location.

Table 2. Prevalence of COVID-19 related Oral and Nasopharyngeal lesions and conditions among different age groups.

Age group	COVID-19 related Oral and Nasopharyngeal lesions and conditions						
	Loss of smell	Loss of taste	Xerostomia	Sore throat	Burning sensation	Ulcers	Vesicles
Below 10 years	1(11.1%)	0(0.0%)	2(22.2%)	2(22.2%)	1(11.1%)	1(11.1%)	0(0.0%)
10 to 20 years	7(38.9%)	7(38.9%)	3(16.7%)	1(5.6%)	1(5.6%)	0(0.0%)	1(5.6%)
21 to 30 years	37(75.5%)	30(61.2%)	11(23.4%)	8(17.0%)	6(12.2%)	4(8.5%)	4(8.5%)
31 to 40 years	27(75.0%)	22(61.1%)	5(13.9%)	5(14.3%)	1(2.8%)	4(11.1%)	3(8.6%)
41 years to 50 years	19(65.5%)	17(58.6%)	9(31.0%)	10(34.5%)	6(20.7%)	3(10.3%)	1(3.4%)
51 years and above	8(42.1%)	7(36.8%)	5(26.3%)	4(22.2%)	3(15.8%)	1(5.3%)	2(10.5%)
p value*	<0.001**	0.007*	0.65	0.03*	0.28	0.77	0.85

p values based on Chi-square test; considered statistically significant at $p \leq 0.05$

Table 3. Prevalence of COVID-19 related Oral and Nasopharyngeal lesions and conditions among Males and Females.

Gender	COVID-19 related Oral and Nasopharyngeal lesions and conditions						
	Loss of smell	Loss of taste	Xerostomia	Sore throat	Burning sensation	Ulcers	Vesicles
Males	42(56.8%)	37(50.0%)	7(36.8%)	13(17.6%)	6(8.1%)	7(9.5%)	4(5.4%)
Females	57(66.3%)	46(53.5%)	7(43.8%)	17(20.7%)	12(14.0%)	6(7.1%)	7(8.4%)
p value*	0.14	0.38	0.47	0.38	0.18	0.41	0.33

p values based on Chi-square test; considered statistically significant at $p \leq 0.05$

Table 4. Odds' ratios showing 95% confidence interval and strength of association between Oral/Nasopharyngeal lesions or conditions and Covid-19 related systemic symptoms.

Covid-19 symptoms		Odds' ratios		Xerostomia		Sore throat		Burning sensation	
		Loss of smell	Loss of taste	Xerostomia	Sore throat	Burning sensation			
Cough		2.1095 (95% CI, 1.100±4.047)	4.6742 (95% CI, 2.371±9.213)	2.8209 (95% CI, 1.188±6.700)	2.7143 (95% CI, 1.086±6.783)	3.99 (95% CI, 1.105±14.385)			
p value		0.0247	0.0001	0.0188	0.0326	0.0346			
Headache		2.7556 (95% CI, 1.411±5.380)	3.0692 (95% CI, 1.566±6.015)	1.8489 (95% CI, 0.798±4.283)	6.5342 (95% CI, 1.883±22.673)	2.1477 (95% CI, 0.672±6.863)			
p value		0.0030	0.0011	0.1516	0.0031	0.1972			
Body pain		3.1250 (95% CI, 1.518±6.433)	4.6545 (95% CI, 2.134±10.151)	2.4828 (95% CI, 0.892±6.908)	6.2759 (95% CI, 1.424±7.664)	16.1759 (95% CI, 1.311±20.113)			
p value		0.0020	0.0001	0.0816	0.0152	0.0540			
Fatigue		3.6024 (95% CI, 1.720±7.546)	4.1779 (95% CI, 1.910±9.137)	3.3343 (95% CI, 1.099±10.121)	3.8864 (95% CI, 1.111±13.592)	15.13 (95% CI, 9.463±20.514)			
p value		0.0007	0.0003	0.0335	0.0336	0.05			
Dizziness		2.0371 (95% CI, 1.065±3.895)	1.8227 (95% CI, 0.973±3.414)	1.4758 (95% CI, 0.688±3.165)	3.7312 (95% CI, 1.494±9.321)	2.0000 (95% CI, 0.711±5.623)			
p value		0.0315	0.0608	0.3175	0.0048	0.1888			
Fever		0.6619 (95% CI, 0.346±1.265)	1.0916 (95% CI, 0.586±2.035)	2.4597 (95% CI, 1.090±5.552)	1.8769 (95% CI, 0.814±4.329)	1.3647 (95% CI, 0.500±3.722)			
p value		0.2115	0.7826	0.0302	0.1397	0.5436			
Subjective Fever		3.9819 (95% CI, 1.998±7.937)	3.4890 (95% CI, 1.817±6.698)	2.4491 (95% CI, 1.119±5.362)	7.6000 (95% CI, 2.729±21.168)	10.6230 (95% CI, 2.354±47.946)			
p value		0.0001	0.0002	0.0251	0.0001	0.0021			
Shortness of breath		2.7595 (95% CI, 1.211±6.287)	3.9942 (95% CI, 1.796±8.885)	2.0049 (95% CI, 0.897±4.483)	3.3654 (95% CI, 1.457±7.772)	4.4758 (95% CI, 1.628±12.306)			
p value		0.0157	0.0007	0.0903	0.0045	0.0037			
Runny nose		1.7602 (95% CI, 0.892±3.472)	1.3611 (95% CI, 0.715±2.591)	1.6241 (95% CI, 0.758±3.481)	2.0732 (95% CI, 0.925±4.646)	2.9825 (95% CI, 1.088±8.179)			
p value		0.1029	0.3480	0.2125	0.0766	0.0337			
Nasal congestion		5.3000 (95% CI, 2.282±12.308)	2.9202 (95% CI, 1.449±5.887)	2.1173 (95% CI, 0.979±4.581)	6.6897 (95% CI, 2.817±15.889)	5.1000 (95% CI, 1.792±14.515)			
p value		0.0001	0.0027	0.0548	0.0001	0.0023			
Diarrhea		0.9919 (95% CI, 0.520±1.891)	1.0771 (95% CI, 0.575±2.018)	1.5459 (95% CI, 0.727±3.286)	4.0580 (95% CI, 1.716±9.599)	1.8103 (95% CI, 0.674±4.863)			
p value		0.9803	0.8165	0.2576	0.0014	0.2391			

Anosmia, Ageusia, Sore throat and Burning Sensation showed statistically significant ($p \leq 0.05$) association with symptoms of Body pain and Shortness of Breath. The strongest predictor was observed for occurrence of burning sensation and body pain (OR=16.18) which indicates that there was 16 times more chances of burning sensation to be reported among those with COVID-19 related body pain than without. Statistically significant association ($p \leq 0.05$) of symptoms like fever, runny nose and Diarrhea were limited only to oral findings like xerostomia, burning sensation and sore throat respectively.

Discussion

The disastrous impacts of the widespread COVID-19 pandemic on all sectors has detrimentally afflicted the quality of life globally. Though two years have elapsed, coexisting with Covid-19 seems to have become the 'New normal' as the world has recognized and accepted the reality that Covid-19 and its mutant variants are here to stay for quite a long time.¹⁷

With the development and easy availability of COVID-19 vaccines, most countries are now relaxing the restrictions for wearing masks and socializing as an attempt to resolve the economic, social and medical burden which are resultant aftermath of the pandemic. So, it is quite normal for undiagnosed COVID-19 patients or carriers to spend time with healthy individuals during social or official gatherings, which can initiate waves of fresh infection. For the same reason the dental fraternity should be cautious about infectious carriers of COVID-19 who might present themselves for routine dental treatment procedures. It is said that oral health mirrors general health; surprisingly till date there is only scanty data related to the prevalence of oral lesions and its association with other COVID-19 related symptoms. Much of the available literature in this field is in the form of case reports, case series and systematic reviews making completely valid and meaningful comparisons with other similar observational studies a difficult challenge.

In the present study oral symptoms were significantly associated with many of the COVID-19 related general symptoms showing that these could be suitable predictors for confirmation of COVID-19 without waiting for diagnostic test reports.

Anosmia, sore throat, ageusia, burning sensation and xerostomia were among the most prevalent Oral and Nasopharyngeal lesions or conditions reported by the respondents of the present study. Orilisi *et al.* in their systematic review mentioned the occurrence of functional disorders like xerostomia, ageusia, dysgeusia and burning mouth as early manifestations of hospitalized patients affected by COVID-19 infection.¹⁸ This is in accordance with the findings of current study where these commonly reported symptoms had begun before initiation of COVID-19 related treatment. This indicates that these findings can be attributed as distinguishing features of COVID-19 and not as any side effects of drugs used for COVID-19 treatment.

According to the present study, Anosmia and Ageusia, were reported by 61.9% and 51.9% of the study subjects respectively. This is similar to the conclusions made by Mullo *et al.*, in their review article stating that Smell impairment is frequent and presents as an early and abruptly occurring distinguishing symptom in COVID-19 in at least 1 out of 5 patients.¹⁹ Anosmia and Ageusia, were the most reported differentiating symptoms among COVID-19 patients in studies by Kumar *et al.*²⁰ Ageusia was a dominant symptom noted in other observational studies by Ganesan *et al.*, (51.2%)²¹, Elkady *et al.*, (34.5%)²² and Natto *et al.*, (43.4%)²³ The incidence of smell and/or taste disorders ranged from 5% to 98%, based upon on region of the study and study design.¹⁹ There is substantial evidence that loss of Anosmia or Ageusia is strongly linked with COVID-19 and can be used as questions to screen the patients in medicine and dentistry clinics to limit the risk of disease transmission.²⁴

Xerostomia was yet another prominently reported symptom in this study, with a prevalence of 22.1% which was consistent with the findings of Ganesan *et al.*,²¹ and Elkady *et al.*,²². However, in a case series by Fathi *et al.*, 60% of cases gave history of dry mouth, 3–4 days prior as a prodromal symptom which was not in agreement to our results.²⁵ Soares *et al.*, detected COVID-19 virus in the vacuolated cells of the superficial epithelium and also in the salivary glands of COVID-19 patients, indicating that salivary glands can be considered as a viral pool and saliva may possibly be the main source of the contagion.²⁶

Sore throat was prevalent among 19.2% of current respondents which did not tally with studies by Savtale *et al.*, (47.2%)²⁷, or Alsofayan *et al.*, (81.6%)²⁸ but was in close alignment with reports by Al-Omari *et al.*, (21.9%)²⁹ and Biadsee *et al.*, (26.6%)³⁰. The difference could have been due to difference in age groups, gender or presence of other comorbidities among the study subjects.

In the current study, ulcers, vesicles, and papules were also more or less frequently found findings. Such lesions might result from different conditions like infections, poor oral hygiene, immunosuppression states, trauma or neoplasms.^{18,31} An elevated level of tumor necrosis factor (TNF)- α in individuals with COVID-19 can lead to chemotaxis of neutrophils

to the oral mucosa and thus growth of aphthous-like lesions. Other plausible reasons for the formation of such lesions in these patients include concomitant stress and immunosuppression brought on by the COVID-19 infection.¹⁴ These oral lesions thereby cannot be considered as COVID-19 specific manifestations.

General systemic symptoms like Fatigue, Body pain, Headache, Cough, Fever, Dizziness, Subjective fever, Diarrhea, Runny nose, Nasal congestion, and Shortness of Breath were commonly prevalent among our study subjects which were similar to observations by Al-Omari *et al.*,²⁹ and Rothan *et al.*³²

Based on calculated odds ratios for the present study which showed statistically significant association, Anosmia was twice more likely to be present among those with cough and dizziness, thrice more common among those with headache, body pain and shortness of breath, four times commonly associated with subjective fever and five times with nasal congestion; whereas loss of taste was thrice more likely to occur in subjects with headache, four times with fatigue, subjective fever and shortness of breath and five times more likely to be found among those with cough and body pain. According to Kumar *et al.*,²⁰ the association between olfactory or gustatory impairment and fever was substantial and favourable (Odds ratio = 10.60) which was higher than $OR \approx 4$ in our study; positive association was also reported with diarrhea (Odds ratio = 4.86); however, no significant association was detected for loss of taste or smell with occurrence of diarrhea in the present study. The difference in the age groups considered for both studies could be a possible explanation for the differences in odds ratios observed. The current study also showed $OR \approx 3$, associating xerostomia with fatigue, fever and cough and $OR \approx 2$ for association with nasal congestion but no possible comparative studies were available associating xerostomia, sore throat or burning sensation with COVID-19 general symptoms.

Conclusion & limitations

The results of this study indicate that the presence of olfactory (smell) or gustatory (taste) dysfunction, dry mouth, sore throat, and a burning sensation, along with COVID-19 generic symptoms, should be regarded as suggestive but not definite markers of COVID-19. In spite of the fact that the research was only conducted in Eastern Province, it was able to identify and include the very first cases of COVID-19 in the Eastern Province of the Kingdom of Saudi Arabia. In addition to this, the social factors of the patients were accounted for, and the sample size was adequate, covering a broad spectrum of clinical data. It was unable to fully analyse the clinical data for some patients because there was insufficient information available regarding the frequency and duration of these patients' self-reported symptoms. Further research is definitely required and should include parameters like viral load, quantitative assessment of symptoms and evaluation of histopathological parameters to confirm the extent of cause effect relation between oral and systemic findings of COVID-19. With detailed oral screening, dental professionals are in an optimal position to take adequate precautions for prevention and timely intervention for early diagnosis and prompt treatment to avoid potential complications and community spread.

Data availability

Underlying data

Figshare: Data set - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire based hypothetical study, <https://doi.org/10.6084/m9.figshare.21546324.v1>.³³

Extended data

Figshare: Questionnaire - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID -19): A questionnaire based hypothetical study, <https://doi.org/10.6084/m9.figshare.21528999.v1>.³⁴

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0).

References

- Sharma A, Ahmad Farouk I, Lal SK: **COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention.** *Viruses.* 2021 Jan 29; **13**(2): 202 (1-25).
[PubMed Abstract](#) | [Publisher Full Text](#)
- Harvey WT, Carabelli AM, Jackson B: **SARS-CoV-2 variants, spike mutations and immune escape.** *Nat. Rev. Microbiol.* 2021; **19**: 409–424.
[PubMed Abstract](#) | [Publisher Full Text](#)
- WHO Coronavirus disease 2019 (COVID-19) Situation Report- September 21, 2021. Edition 58.
- Peng X, Xu X, Li Y, *et al.*: **Transmission routes of 2019-nCoV and controls in dental practice.** *Int. J. Oral Sci.* 2020 Mar. 3; **12**(1): 1–6.
[Publisher Full Text](#)
- Ren YF, Rasubala L, Malmstrom H, *et al.*: **Dental Care and Oral Health under the Clouds of COVID-19.** *JDR Clin Trans Res.* 2020 Jul; **5**(3): 202–210.
[PubMed Abstract](#) | [Publisher Full Text](#)
- "Loss of Smell and Taste a Key Symptom for Covid-19 Cases." King's College London, 1 Apr. 2020.
[Reference Source](#)

7. Huang C, Wang Y, Li X: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020; **395**(10223): 497–506.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Tsuchiya H: **Oral Symptoms Associated with COVID-19 and Their Pathogenic Mechanisms: A Literature Review.** *Dent J (Basel).* 2021; **9**(3).
[Publisher Full Text](#)
9. Mahmoud MM, Abuhashish HM, Khairy DA, et al.: **Pathogenesis of dysgeusia in COVID-19 patients: a scoping review.** *Eur. Rev. Med. Pharmacol. Sci.* 2021; **25**(2): 1114–1134.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Jarrahi A, Ahluwalia M, Khodadadi H: **Neurological consequences of COVID-19: what have we learned and where do we go from here?** *J. Neuroinflammation.* 2020; **17**(1): 296.
[Publisher Full Text](#)
11. Eshraghi AA, Mirsaeidi M, Davies C, et al.: **Potential Mechanisms for COVID-19 Induced Anosmia and Dysgeusia.** *Front. Physiol.* 2020; **11**(1039).
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Alexandre J, Cracowski JL, Richard V, et al.: **Renin-angiotensin-aldosterone system and COVID-19 infection.** *Ann. Endocrinol.* 2020; **81**(2–3): 63–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Harikrishnan P: **Etiogenic Mechanisms for Dysgeusia in SARS-CoV-2 Infection.** *J. Craniofac. Surg.* 2021; **32**(1): e111–e112.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Iranmanesh B, Khalili M, Amiri R, et al.: **Oral manifestations of COVID-19 disease: A review article.** *Dermatol. Ther.* 2021; Jan; **34**(1): e14578.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Banakar M, Bagheri Lankarani K, Jafarpour D: **COVID-19 transmission risk and protective protocols in dentistry: a systematic review.** *BMC Oral Health.* 2020; **20**: 275.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. National Health Commission of the People's Republic of China: **Diagnosis guidelines for the new coronavirus pneumonia (NCIP) of the seventh edition.**
17. World Health Organization: **From the “new normal” to a “new future”: A sustainable response to COVID-19.**
18. Orilisi G, Mascitti M, Togni L, et al.: **Oral Manifestations of COVID-19 in Hospitalized Patients: A Systematic Review.** *Int. J. Environ. Res. Public Health.* 2021; **18**(23): 12511.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Mullol J, Alobid I, Mariño-Sánchez F, et al.: **The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries.** *Curr Allergy Asthma Rep.* 2020; **20**(10): 61.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Kumar L, Kahlon N, Jain A, et al.: **Loss of smell and taste in COVID-19 infection in adolescents.** *Int. J. Pediatr. Otorhinolaryngol.* 2021; **142**(110626): 110626.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Ganesan A, Kumar S, Kaur A: **Oral Manifestations of COVID-19 Infection: An Analytical Cross-Sectional Study.** *J. Maxillofac Oral Surg.* 2022; **1**–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. El Kady DM, Gomaa EA, Abdella WS, et al.: **Oral manifestations of COVID-19 patients: An online survey of the Egyptian population.** *Clin Exp Dent Res.* 2021 Oct; **7**(5): 852–860.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Natto ZS, Afeef M, Khalil D, et al.: **Characteristics of Oral Manifestations in Symptomatic Non-Hospitalized COVID-19 Patients: A Cross-Sectional Study on a Sample of the Saudi Population.** *Int J Gen Med.* 2021 Dec; **14**: 9547–9553.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hopkins C, Kelly C: **Prevalence and persistence of smell and taste dysfunction in COVID-19; how should dental practices apply diagnostic criteria?.** *BDJ In Pract.* 2021; **34**: 22–23.
[Publisher Full Text](#)
25. Fathi Y, Hoseini EG, Atoof F, et al.: **Xerostomia (dry mouth) in patients with COVID-19: a case series.** *Futur. Virol.* 2021; **16**: 315–319.
[Publisher Full Text](#)
26. Soares CD, Souza LL, Carvalho MGF, et al.: **Oral Manifestations of Coronavirus Disease 2019 (COVID-19): A Comprehensive Clinicopathologic and Immunohistochemical Study.** *Am. J. Surg. Pathol.* 2022; **46**(4): 528–536.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Savtale S, Hippargekar P, Bhise S, et al.: **Prevalence of Otorhinolaryngological Symptoms in Covid 19 Patients.** *Indian J Otolaryngol Head Neck Surg.* 2021 Feb 8; **1**–7.
28. Alsafyan YM, Althunayyan SM, Khan AA, et al.: **Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study.** *J. Infect. Public Health.* 2020; **13**(7): 920–925.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Al-Omari A, Alhuqbani WN, Zaidi ARZ, et al.: **Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study.** *J. Infect. Public Health.* 2020 Nov; **13**(11): 1639–1644.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Biadsee A, Biadsee A, Kassem F, et al.: **Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis.** *Otolaryngol. Head Neck Surg.* 2020 Oct; **163**(4): 722–728.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Cuevas-Gonzalez MV, Espinosa-Cristóbal LF, Donohue-Cornejo A, et al.: **COVID-19 and its manifestations in the oral cavity: A systematic review.** *Medicine (Baltimore).* 2021 Dec; **23**: **100**(51): e28327.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Rothan HA, Byrareddy SN: **The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.** *J. Autoimmun.* 2020; **109**: 102433.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Mohammed F, Fairuzekhan AT, Mohamed S, et al.: **Data set - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID -19): A questionnaire based hypothetical study.** figshare. Dataset. 2022.
[Publisher Full Text](#)
34. Mohammed F, Fairuzekhan AT, Mohamed S, et al.: **Questionnaire - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID -19): A questionnaire based hypothetical study.** figshare. Dataset. 2022.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 2

Reviewer Report 13 June 2023

<https://doi.org/10.5256/f1000research.147248.r174712>

© 2023 Fared M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Muhammad Amber Fared 

College of Dentistry, Gulf Medical University, Ajman, United Arab Emirates

I'm satisfied with the revisions made by the authors and happy to recommend for this manuscript for indexing.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 25 May 2023

<https://doi.org/10.5256/f1000research.147248.r174713>

© 2023 Acharya S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Shruthi Acharya 

Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India

I appreciate the efforts put in by the authors in addressing the concerns raised.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Oral Cancer Diagnosis, Potentially malignant oral disorders, CBCT, Oral mucosal lesions, Management of oral complications of cancer therapy

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 01 February 2023

<https://doi.org/10.5256/f1000research.140687.r160633>

© 2023 Acharya S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Shruthi Acharya 

Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India

I congratulate the authors for performing the study to understand the oral manifestations of COVID-19 infection. The study was done under challenging circumstances. I appreciate the efforts put in by the authors to conduct the study.

I have a few queries:

1. Kindly justify why the term “hypothetical” is used in the title to describe the study
2. Introduction - well written
3. Patients and Methods - IEC approval was obtained, Inclusion criteria is defined and the questionnaire was vetted.
4. Results
 1. Kindly rephrase and reorder sentences in the first paragraph of the results section.
 2. Children less than 10 years were included in the study - were they able to comprehend and explain their symptoms like papule/ vesicle, etc. over the telephone?
 3. Kindly use uniform spelling for “Diarrhea” in the text and table.
 4. Table 1 - kindly restructure the table. Symptoms with Yes/No response to be put together, Symptoms with Before the treatment/During the treatment/ after treatment responses together.
 5. Figure 3- The text and legends are not visible clearly. Kindly improve the resolution of the figure.

6. Kindly do not unnecessarily capitalize words between a sentence.

7. Table 4 - kindly provide reference categories and 95% confidence intervals for all the variables. Also, provide legends to the tables.

5. Discussion

1. Kindly do not unnecessarily capitalize words between a sentence.

6. Drawbacks of study

1. It can be described as a separate heading.

2. Is there a possibility of recall bias?

7. Conclusion can be clearly stated.

8. References

1. Some references are not complete.

2. References should have both start and end page numbers.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Oral Cancer Diagnosis, Potentially malignant oral disorders, CBCT, Oral mucosal lesions, Management of oral complications of cancer therapy

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 May 2023

FARAZ MOHAMMED

Reviewer comment: Kindly justify why the term “hypothetical” is used in the title to describe the study.

Authors Reply: The term hypothetical was used in the title because, this study was conducted in the very early phase of COVID-19 era. At that particular time no data was published on the oral manifestations associated with COVID-19 except for loss of taste. Since we knew few oral signs & symptoms of few other viral infections, we took this study as a hypothetical study.

Reviewer comment: Introduction - well written

Authors Reply: Thank you so much

Reviewer comment: Kindly rephrase and reorder sentences in the first paragraph of the results section.

Authors Reply: Thank you so much for the constructive comment. We have now rephrased and reordered sentences in the first paragraph of the results section.

Reviewer comment: Children less than 10 years were included in the study - were they able to comprehend and explain their symptoms like papule/ vesicle, etc. over the telephone?

Authors Reply: Since the questionnaire was drafted both in English and Arabic languages. Moreover, the doctors who interviewed these patients were well versed in the native language and they could clearly explain to the patient. At times we took the help of the parents.

Reviewer comment: Kindly use uniform spelling for “Diarrhea” in the text and table.

Authors Reply: Sorry, we have now used the uniform spelling.

Reviewer comment: Kindly do not unnecessarily capitalize words between a sentence.

Authors Reply: Sorry, we have now removed the unnecessarily capitalize words from between a sentence.

Reviewer comment: Table 4 - kindly provide reference categories and 95% confidence intervals for all the variables. Also, provide legends to the tables.

Authors Reply: We have now provided 95% confidence intervals for all the variables. The legends to the table are also provided.

Discussion

Reviewer comment: Kindly do not unnecessarily capitalize words between a sentence.

Authors Reply: Sorry, we have now removed the unnecessarily capitalize words from between a sentence.

Drawbacks of study

Reviewer comment: It can be described as a separate heading.

Authors Reply: Yes, we have now included a separate paragraph as “Conclusion & Limitations”.

Reviewer comment: Is there a possibility of recall bias?

Authors Reply: This study was conducted in the very early phase of COVID-19 where the patients had just recovered from COVID-19 infection, thereby there was very less chances of patients forgetting a past events of their infection. Moreover, 230 patients participated in this study. But, only 179 COVID-19 patients were included for the statistical analysis as few of them did not respond to most questions. So completely elimination the recall bias.

Conclusion

Reviewer comment: Conclusion can be clearly stated.

Authors Reply: Yes, we have now included a separate paragraph as "Conclusion".

References

Reviewer comment: Some references are not complete.

Authors Reply: Now we have updated the references according to the journal norms. Most of the articles from the MDPI journals have a single page number. And the references are automatically generated according to journal norms.

Reviewer comment: References should have both start and end page numbers.

Authors Reply: Now we have updated the references according to the journal norms.

Competing Interests: No competing interests to disclose.

Reviewer Report 16 January 2023

<https://doi.org/10.5256/f1000research.140687.r157555>

© 2023 Fared M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Muhammad Amber Fared 

College of Dentistry, Gulf Medical University, Ajman, United Arab Emirates

I've reviewed the manuscript titled "Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire-based hypothetical study" with interest. The authors of this study presented data on the correlation between the severity of COVID-19 infection and oral symptoms while distinguishing oral signs and symptoms among ambulatory and non-hospitalized COVID-19 patients presented in Saudi Arabia during the COVID-19 pandemic outbreak in 2020. This is useful and relevant research in relation to the most recent pandemic condition of the COVID-19 pandemic. The finding of this study certainly provides some recommendations and supports health workers to better understand COVID-19 manifestation of oral conditions.

Please, find my following comments and questions about this manuscript:

- The title and abstract look ok as they cover the main idea and condense the key findings.

- Introduction: The authors have provided a brief overview and introduction to the topic and have highlighted several underlying mechanisms for COVID-19-related oral manifestations. It would be interesting if the authors may clarify and include a similar study using the patient interview and may comment on whether earlier research had some limitations and use these gaps to explain the novelty of this research. Please also provide any relevant recent references on the same topic from Saudi Arabia to explain whether similar studies that reported the oral manifestations associated with coronavirus disease.
- Method: Please provide more details on how the sample size was calculated.
- Discussion: Authors have provided a reasonable argument to support the finding of this study however, I would encourage authors to discuss the finding of this work in relation to the case reports published including the parameters on viral load, quantitative assessment of symptoms and evaluation of histopathological parameters.
- The conclusions are missing.
- It would be a good idea to provide the "comprehensive survey questionnaire" as additional resource.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Dental biomaterials and restorative dentistry research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 May 2023

FARAZ MOHAMMED

ABSTRACT

Reviewer comment: The title and abstract look ok as they cover the main idea and condense the key findings.

Authors Reply: Thank you so much for your constructive comment.

Introduction:

Reviewer comment: The authors have provided a brief overview and introduction to the topic and have highlighted several underlying mechanisms for COVID-19-related oral manifestations. It would be interesting if the authors may clarify and ***include a similar study using the patient interview and may comment on whether earlier research had some limitations and use these gaps to explain the novelty of this research.*** Please also provide any relevant recent references on the same topic from Saudi Arabia to explain whether similar studies that reported the oral manifestations associated with coronavirus disease.

Authors Reply: The authors have now included a similar study using the patient interview and also have commented on the limitations and gaps from the previous studies. As far as the other concern of the esteemed reviewer to include a similar study from Saudi Arabia, we the authors like to inform our reviewer that, our study was the very first study to be carried out in the Kingdom of Saudi Arabia during the period 21/08/2020 to 07/12/2020, further that no similar studies were published from the Kingdom of Saudi Arabia when we first submitted our manuscript for publication.

Method:

Reviewer comment: ***Please provide more details on how the sample size was calculated. - Given in the result section.***

Authors Reply: A convenience sampling method was adopted for recruiting participants in this study. As it was considerably difficult to get study participants because of the infectious nature of the disease and the social stigma associated with strict COVID-19 protocols, all participants who fulfilled the inclusion requirements and consented were recruited in the study; hence sample size was not taken into consideration. *This statement is been included in the manuscript.*

Discussion:

Reviewer comment: Authors have provided a reasonable argument to support the finding of this study however, I would encourage authors to discuss the finding of this work in relation to the case reports published including the parameters on viral load, quantitative assessment of symptoms and evaluation of histopathological parameters.

Authors Reply: Thank you so much for your constructive comment on the written discussion. We have already included the case reports and correlated and discussed the findings elaborately in the manuscript. But for the comment to include and discuss the evaluation of histopathological parameters, we the authors have not taken any biopsy from the studied samples due to the fact considerably difficult to get study participants because of the infectious nature of the disease and the social stigma associated with strict COVID-19 protocols. So we could not discuss this aspect in our manuscript.

Conclusion:

Reviewer comment: The conclusions are missing.

Authors Reply: Earlier the conclusion was merged in the discussion paragraph itself. Now the conclusion and limitations part are separated from the discussion part and added separately in the manuscript.

Reviewer comment: It would a good idea to provide the “comprehensive survey questionnaire” as additional resource.

Authors Reply: Yes, the authors have already provided and also deposited the “comprehensive survey questionnaire” as well as the complete “data set” in Repository with the following hyperlinks:

Data availability**Underlying data**

Figshare: Data set - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire based hypothetical study,

<https://doi.org/10.6084/m9.figshare.21546324.v1>

Extended data

Figshare: Questionnaire - Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID -19): A questionnaire based hypothetical study,

<https://doi.org/10.6084/m9.figshare.21528999.v1>

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Competing Interests: No competing interests to disclose.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research